AAA May 2017 – Page 20

Aadi re-accesses Celgene for $23m series A

Pharmaceutical company Celgene has participated in a $23m series A round for US-based clinical stage biopharmaceutical company Aadi Bioscience. The round was led by healthcare-focused private equity firm Hermed Capital and also featured Vivo Capital, Decheng Capital, Star Summit Ventures and Helsinn Investment Fund. Aadi Bioscience is working on a drug candidate dubbed ABI-009 which… Continue reading Aadi re-accesses Celgene for $23m series A